Breast Cancer, Sentinel Lymph Node
Conditions
Brief summary
Objective: To investigate the current clinical practice of sentinel lymph node biopsy (SLNB) in patients with early stage breast cancer in China. Methods: The data of early breast cancer patients who underwent SLNB in 40 Grade III Level A hospitals in China in 2018 will be collected. Different centers, tracer methods, molecular typing and neoadjuvant chemotherapy will be used as stratification factors to analyze the implementation rate, number of detections, positive rate of SLNB and the follow-up treatment.
Interventions
DIAGNOSTIC_TESTmapping agent
according to different tracer methods, patients are divided into the implementation of a single mapping agent and implementation of combination of blue dye and radiotracer agent.
PROCEDUREneoadjuvant chemotherapy
Patients were divided into two groups based on whether they were receiving neoadjuvant chemotherapy.
Sponsors
Xijing Hospital
Study design
Observational model
COHORT
Time perspective
RETROSPECTIVE
Eligibility
Sex/Gender
ALL
Healthy volunteers
No
Inclusion criteria
* breast cancer confirmed by fine needle aspiration or biopsy * SLNB with or without axillary lymph node dissection * receiving conventional systematic treatment or regional treatment * complete medical record.
Exclusion criteria
* IV stage breast cancer * combined with secondary invasive malignant tumor * diagnosed with other serious disease, including congestive heart failure (NYHA cardiac function grade II, III, IV) or congestive heart failure, unstable angina pectoris, myocardial infarction, high-risk uncontrollable heart rate disorder or other serious cardiovascular diseases within 6 months * difficulty breathing at rest or need oxygen therapy * severe infection * uncontrolled diabetes * serious psychological or mental disorders * poor compliance.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| the performance rate of sentinel lymph node biopsy (SLNB) in patients with early stage breast cancer in China | 2020-12-31 | the performance rate of SLNB refers to the number of patients implementing SLNB divided by the total number of breast cancer patients |
| the positive rate of SLNs in patients with early stage breast cancer in China | 2020-12-31 | SLNs positive rate is the number of positive SLN patients divided by the number of patients implementing SLNB |
| the number of resected SLNs in patients with early stage breast cancer in China | 2020-12-31 | the average number of resected SLNB will be calculated |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| incidence of infection events after SLNB in patients with early stage breast cancer in China | 2021-12-31 | incidence of infection events is the number of patients who have an infection event after SLNB divided by the total number of patients implementing SLNB. The infection events include incision infection, local skin infection and injured vascular infection. |
Countries
China
Contacts
Primary ContactJuliang Zhang
Outcome results
None listed